{"id":"https://openalex.org/W1968422076","doi":"https://doi.org/10.1161/strokeaha.108.540708","title":"Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale","display_name":"Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale","publication_year":2009,"publication_date":"2009-04-16","ids":{"openalex":"https://openalex.org/W1968422076","doi":"https://doi.org/10.1161/strokeaha.108.540708","mag":"1968422076","pmid":"https://pubmed.ncbi.nlm.nih.gov/19372447","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2881642"},"language":"en","primary_location":{"id":"doi:10.1161/strokeaha.108.540708","doi":"https://doi.org/10.1161/strokeaha.108.540708","is_oa":false,"landing_page_url":"https://doi.org/10.1161/strokeaha.108.540708","pdf_url":null,"source":{"id":"https://openalex.org/S62532593","display_name":"Stroke","issn_l":"0039-2499","issn":["0039-2499","1524-4628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2881642","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000895141","display_name":"Maarten G. Lansberg","orcid":"https://orcid.org/0000-0002-3545-6927","observed_orcids":["https://orcid.org/0000-0002-3545-6927"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","DE","US"],"is_corresponding":false,"raw_author_name":"Maarten G. Lansberg","raw_affiliation_strings":["From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","Maarten G. Lansberg From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2800231306","https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Maarten G. Lansberg From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","institution_ids":["https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066574699","display_name":"Maarten Schrooten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","DE","US"],"is_corresponding":false,"raw_author_name":"Maarten Schrooten","raw_affiliation_strings":["From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","Maarten Schrooten From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2800231306","https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Maarten Schrooten From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","institution_ids":["https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005137653","display_name":"Erich Bluhmki","orcid":"https://orcid.org/0000-0002-3846-7226","observed_orcids":["https://orcid.org/0000-0002-3846-7226"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","DE","US"],"is_corresponding":false,"raw_author_name":"Erich Bluhmki","raw_affiliation_strings":["From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","Erich Bluhmki From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2800231306","https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Erich Bluhmki From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","institution_ids":["https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039943736","display_name":"Vincent Thijs","orcid":"https://orcid.org/0000-0002-6614-8417","observed_orcids":["https://orcid.org/0000-0002-6614-8417"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","DE","US"],"is_corresponding":false,"raw_author_name":"Vincent N. Thijs","raw_affiliation_strings":["From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","Vincent N. Thijs From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2800231306","https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","institution_ids":[]},{"raw_affiliation_string":"Vincent N. Thijs From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","institution_ids":["https://openalex.org/I4210137306"]},{"raw_affiliation_string":"the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075359983","display_name":"Jeffrey L. Saver","orcid":"https://orcid.org/0000-0001-9141-2251","observed_orcids":["https://orcid.org/0000-0001-9141-2251"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]},{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]},{"id":"https://openalex.org/I4210137306","display_name":"Stanford Medicine","ror":"https://ror.org/03mtd9a03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I99464096","display_name":"KU Leuven","ror":"https://ror.org/05f950310","country_code":"BE","type":"education","lineage":["https://openalex.org/I99464096"]}],"countries":["BE","DE","US"],"is_corresponding":false,"raw_author_name":"Jeffrey L. Saver","raw_affiliation_strings":["From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","Jeffrey L. Saver From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif; the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium; Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium; Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany; and the Stroke Center and Department of Neurology (J.L.S.), David Geffen School of Medicine at UCLA, Los Angeles, Calif","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I2800231306","https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Boehringer Ingelheim Pharma GmbH & Co (E.B.), Ingelheim, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Jeffrey L. Saver From the Stanford Stroke Center (M.G.L.), Stanford University Medical Center, Palo Alto, Calif","institution_ids":["https://openalex.org/I4210137306"]},{"raw_affiliation_string":"Vesalius Research Center (V.N.T.), Flemish Institute Biotechnology, Leuven, Belgium","institution_ids":[]},{"raw_affiliation_string":"the Department of Neurology (M.S., V.N.T.), University Hospitals of Leuven, Leuven, Belgium","institution_ids":["https://openalex.org/I99464096"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":9.1528,"has_fulltext":false,"cited_by_count":220,"citation_normalized_percentile":{"value":0.9846303,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":98,"max":100},"biblio":{"volume":"40","issue":"6","first_page":"2079","last_page":"2084"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10227","display_name":"Acute Ischemic Stroke Management","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10292","display_name":"Acute Myocardial Infarction Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tissue-plasminogen-activator","display_name":"tissue plasminogen activator","score":0.9760000109672546},{"id":"https://openalex.org/keywords/acute-ischemic-stroke","display_name":"acute ischemic stroke","score":0.8870000243186951},{"id":"https://openalex.org/keywords/number-needed-to-treat","display_name":"number needed to treat","score":0.9079999923706055},{"id":"https://openalex.org/keywords/treatment-window","display_name":"therapeutic time window","score":0.847000002861023},{"id":"https://openalex.org/keywords/intravenous-thrombolysis","display_name":"intravenous thrombolysis","score":0.8650000095367432},{"id":"https://openalex.org/keywords/modified-rankin-scale","display_name":"modified Rankin Scale","score":0.7689999938011169},{"id":"https://openalex.org/keywords/functional-outcome","display_name":"functional outcome","score":0.8500000238418579},{"id":"https://openalex.org/keywords/benefit-harm-balance","display_name":"benefit-harm balance","score":0.7089999914169312},{"id":"https://openalex.org/keywords/computer-simulation","display_name":"computer simulation","score":0.527999997138977}],"concepts":[{"id":"https://openalex.org/C67774102","wikidata":"https://www.wikidata.org/wiki/Q614132","display_name":"Number needed to treat","level":4,"score":0.8960247039794922},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8711969256401062},{"id":"https://openalex.org/C142454548","wikidata":"https://www.wikidata.org/wiki/Q7069573","display_name":"Number needed to harm","level":5,"score":0.5744889378547668},{"id":"https://openalex.org/C2780931571","wikidata":"https://www.wikidata.org/wiki/Q568775","display_name":"Modified Rankin Scale","level":4,"score":0.5584384799003601},{"id":"https://openalex.org/C2776572282","wikidata":"https://www.wikidata.org/wiki/Q416351","display_name":"Tissue plasminogen activator","level":2,"score":0.5509296655654907},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.48726144433021545},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3704144358634949},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3114835023880005},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24311330914497375},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.2355535924434662},{"id":"https://openalex.org/C3020199598","wikidata":"https://www.wikidata.org/wiki/Q12202","display_name":"Ischemic stroke","level":3,"score":0.1731819212436676},{"id":"https://openalex.org/C541997718","wikidata":"https://www.wikidata.org/wiki/Q188151","display_name":"Ischemia","level":2,"score":0.12334644794464111}],"mesh":[{"descriptor_ui":"D000208","descriptor_name":"Acute Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000367","descriptor_name":"Age Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000465","descriptor_name":"Algorithms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003198","descriptor_name":"Computer Simulation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005343","descriptor_name":"Fibrinolytic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D005343","descriptor_name":"Fibrinolytic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010959","descriptor_name":"Tissue Plasminogen Activator","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D010959","descriptor_name":"Tissue Plasminogen Activator","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012737","descriptor_name":"Sex Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015912","descriptor_name":"Thrombolytic Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020521","descriptor_name":"Stroke","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1161/strokeaha.108.540708","doi":"https://doi.org/10.1161/strokeaha.108.540708","is_oa":false,"landing_page_url":"https://doi.org/10.1161/strokeaha.108.540708","pdf_url":null,"source":{"id":"https://openalex.org/S62532593","display_name":"Stroke","issn_l":"0039-2499","issn":["0039-2499","1524-4628"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"journal-article"},{"id":"pmid:19372447","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19372447","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Stroke","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2881642","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2881642","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Stroke","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2881642","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2881642","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Stroke","raw_type":"Text"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2752730189","display_name":"Who Benefits from tPA 3-6 hours after Stroke","funder_award_id":"K23NS051372","funder_id":"https://openalex.org/F4320337359","funder_display_name":"National Institute of Neurological Disorders and Stroke"}],"funders":[{"id":"https://openalex.org/F4320337359","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":9,"referenced_works":["https://openalex.org/W31674920","https://openalex.org/W205495280","https://openalex.org/W1972257422","https://openalex.org/W2060832182","https://openalex.org/W2098032054","https://openalex.org/W2101200420","https://openalex.org/W2111149452","https://openalex.org/W2159233098","https://openalex.org/W4240994847"],"related_works":["https://openalex.org/W1999286290","https://openalex.org/W1972257422","https://openalex.org/W2548945162","https://openalex.org/W2094034007","https://openalex.org/W2066063283","https://openalex.org/W3145965551","https://openalex.org/W2039392119","https://openalex.org/W1987416673","https://openalex.org/W2099724904","https://openalex.org/W2002318205"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"PURPOSE:":[2],"To":[3],"make":[4,262],"informed":[5,264],"treatment":[6,43,53,99,161,169,178,265],"decisions,":[7],"patients":[8,152,257],"and":[9,18,32,36,105,156,164,172,175,181,205,251],"physicians":[10],"need":[11],"to":[12,27,40,51,209,238,261],"be":[13,259],"aware":[14],"of":[15,20,47,64,74,83,116,231],"the":[16,61,75,146,197,236],"benefits":[17],"risks":[19],"a":[21,42,136,232],"proposed":[22],"treatment.":[23],"The":[24,45,70,93,184,191,242],"number":[25],"needed":[26],"treat":[28],"(NNT)":[29],"for":[30,90,103,107,122,141,151,193,196,245],"benefit":[31,104,123,142,223,234],"harm":[33,108,194],"are":[34,201],"intuitive":[35,252],"statistically":[37],"valid":[38],"measures":[39],"describe":[41],"effect.":[44],"aim":[46],"this":[48,91],"study":[49],"is":[50,219,228],"calculate":[52],"time-specific":[54],"NNT":[55,102,106,121,140,192,243],"estimates":[56,109,124,143,195,244],"based":[57,112,128,144,254],"on":[58,113,129,145,255],"shifts":[59],"over":[60],"entire":[62],"spectrum":[63],"clinically":[65],"relevant":[66],"functional":[67],"outcomes.":[68],"METHODS:":[69],"pooled":[71],"data":[72,94],"set":[73],"first":[76],"6":[77],"major":[78],"randomized":[79],"acute":[80],"stroke":[81],"trials":[82],"intravenous":[84],"tissue":[85,215],"plasminogen":[86,216],"activator":[87,217],"was":[88],"used":[89],"study.":[92],"were":[95,110,125,149],"stratified":[96],"by":[97,135],"90-minute":[98,247],"time":[100,199,240],"windows.":[101],"determined":[111],"expert":[114,147],"generation":[115],"joint":[117,130],"outcome":[118,131],"distribution":[119,132],"tables.":[120],"also":[126],"calculated":[127],"tables":[133],"generated":[134],"computer":[137,185],"model.":[138],"RESULTS:":[139],"panel":[148],"3.6":[150],"treated":[153],"between":[154,162,170,179],"0":[155],"90":[157],"minutes,":[158,166,174],"4.3":[159],"with":[160,168,177,221],"91":[163],"180":[165],"5.9":[167],"181":[171],"270":[173],"19.3":[176],"271":[180],"360":[182],"minutes.":[183],"simulation":[186],"yielded":[187],"very":[188],"similar":[189],"results.":[190],"corresponding":[198],"intervals":[200],"65,":[202],"38,":[203],"30,":[204],"14.":[206],"CONCLUSIONS:":[207],"Up":[208],"4(1/2)":[210],"hours":[211],"after":[212],"symptom":[213],"onset,":[214],"therapy":[218],"associated":[220],"more":[222],"than":[224],"harm,":[225],"whereas":[226],"there":[227],"no":[229],"evidence":[230],"net":[233],"in":[235],"4(1/2)-":[237],"6-hour":[239],"window.":[241],"each":[246],"epoch":[248],"provide":[249],"useful":[250],"information":[253],"which":[256],"may":[258],"able":[260],"better":[263],"decisions.":[266]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":9},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":19},{"year":2020,"cited_by_count":13},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":13},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":20},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":20},{"year":2012,"cited_by_count":16}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}